Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment

Nature Communications

Volumn 7, Issue , 2016, Pages

  Akimoto, Miho ^a   Maruyama, Riruke ^a   Takamaru, Hiroyuki ^b   Ochiya, Takahiro ^c   Takenaga, Keizo ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b Medicine Center Hospital   (Japan)

^c Center for Medical Genomics   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FC PROTEIN; HYBRID PROTEIN; INTERLEUKIN 33; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 2 FC FUSION PROTEIN; UNCLASSIFIED DRUG; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

CANCER; CELLS AND CELL COMPONENTS; CHEMORECEPTION; GENE EXPRESSION; INHIBITION; RODENT; TUMOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL INFILTRATION; CELL POLARITY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGE; MALE; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; TH1 CELL; TH2 CELL; TUMOR MICROENVIRONMENT; ADENOCARCINOMA; ADULT; AGED; ANIMAL; COLORECTAL TUMOR; GENE KNOCKDOWN; GENETICS; IMMUNOLOGY; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; YOUNG ADULT;

MUS;

ADENOCARCINOMA; ADULT; AGED; ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; MACROPHAGES; MALE; MICE; MIDDLE AGED; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; TH1 CELLS; TH2 CELLS; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84997108003     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13589     Document Type: Article

References (57)

1. Davies, J. M., Goldberg, R. M. First-line therapeutic strategies in metastatic colorectal cancer. Oncology 22, 1470-1479 (2008).
2. Davies, J. M., Goldberg, R. M. Treatment of metastatic colorectal cancer. Semin. Oncol. 38, 552-560 (2011).
3. Tominaga, S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 258, 301-304 (1989).
4. Tago, K. et al. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem. Biophys. Res. Commun. 285, 1377-1383 (2001).
5. Liew, F. Y. IL-33: a Janus cytokine. Ann. Rheum. Dis. 71(Suppl 2): i101-i104 (2012).
6. Trajkovic, V., Sweet, M. J., Xu, D. T1/ST2-an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev. 15, 87-95 (2004).
7. Xu, D. et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J. Exp. Med. 187, 787-794 (1998).
8. Joshi, A. D. et al. Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages. BMC Immunol. 11, 52 (2010).
9. Cherry, W. B., Yoon, J., Bartemes, K. R., Iijima, K., Kita, H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J. Allergy Clin. Immunol. 121, 1484-1490 (2008).
10. Bergers, G., Reikerstorfer, A., Braselmann, S., Graninger, P., Busslinger, M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. Eur. Mol. Biol. Organ. J 13, 1176-1188 (1994).
11. Oshikawa, K., Yanagisawa, K., Tominaga, S., Sugiyama, Y. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin. Exp. Allergy 32, 1520-1526 (2002).
12. Liew, F. Y., Pitman, N. I., McInnes, I. B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 10, 103-110 (2010).
13. Schmitz, J. et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490 (2005).
14. Moussion, C., Ortega, N., Girard, J. P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin' PLoS ONE 3, e3331 (2008).
15. Wood, I. S., Wang, B., Trayhurn, P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem. Biophys. Res. Commun. 384, 105-109 (2009).
16. Oboki, K., Ohno, T., Kajiwara, N., Saito, H., Nakae, S. IL-33 and IL-33 receptors in host defense and diseases. Allergol. Int. 59, 143-160 (2010).
17. Oboki, K. et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl Acad. Sci. USA 107, 18581-18586 (2010).
18. Sun, P. et al. Serum interleukin-33 levels in patients with gastric cancer. Dig. Dis. Sci. 56, 3596-3601 (2011).
19. Hu, L.-A., Fu, Y., Zhang, D.-N., Zhang, J. Serum IL-33 as a diagnostic and prognostic marker in non-small cell lung cancer. Asian Pac. J. Cancer Prev. 14, 2563-2566 (2013).
20. Zhang, P. et al. Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J. Int. Med. Res. 40, 1654-1661 (2012).
21. Jovanovic, I. P. et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int. J. Cancer 134, 1669-1682 (2014).
22. Janakira, N. B., Rao, C. V. The role of inflammation in colon cancer. Adv. Exp. Med. Biol. 816, 25-52 (2014).
23. Maywald, R. L. et al. IL-33 activates tumor stroma to promote intestinal polyposis. Proc. Natl Acad. Sc. i USA 112, E2487-E2496 (2015).
24. Cui, G. et al. Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer. Cancer Immunol. Immunother. 64, 181-190 (2015).
25. Liu, X. et al. IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem. Biophys. Res. Commun. 453, 486-492 (2014).
26. Akimoto, M., Hayashi, J. I., Nakae, S., Saito, H., Takenaga, K. Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer. Cell Death Dis. 7, e2057 (2016).
27. Gao, K. et al. Transgenic expression of IL-33 activates CD8\+ T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett. 335, 463-471 (2013).
28. Gao, X. et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8\+ T and NK cells. J. Immunol. 194, 438-445 (2015).
29. Choi, Y. S. et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 114, 3117-3126 (2009).
30. Demyanets, S. et al. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 31, 2080-2089 (2011).
31. Basu, A. et al. Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res. 68, 5689-5698 (2008).
32. Milovanovic, M. et al. IL-33/ST2 axis in inflammation and immunopathology. Immunol. Res. 52, 89-99 (2012).
33. Cayrol, C., Girard, J. P. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr. Opin. Immunol. 31, 31-37 (2014).
34. Haraldsen, G., Balogh, J., Pollheimer, J., Sponhiem, J., Kuchler, A. M. Interleukin-33-cytokine of dual function or novel alarmin Trends Immunol. 30, 227-233 (2009).
35. Xu, L. L. et al. Monocyte chemotactic protein-3 (MCP3) interacts with multiple leukocyte receptors: binding and signaling of MCP3 through shared as well as unique receptors on monocytes and neutrophils. Eur. J. Immunol. 25, 2612-2617 (1995).
36. Xuan, W., Qu, Q., Zheng, B., Xiong, S., Fan, G. H. The chemotaxis of M1 and M2 macrophages is regulated by different chemokines. J. Leukoc. Biol. 97, 61-69 (2015).
37. Italiani, P., Boraschi, D. From monocytes to M1/M2 macrophages: phenotypical versus functional differentiation. Front. Immunol. 5, 514 (2014).
38. Sica, A. et al. Macrophage polarization in tumour progression. Semin. Cancer Biol. 18, 349-355 (2008).
39. Chanmee, T., Ontong, P., Konno, K., Itano, N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel) 6, 1670-1690 (2014).
40. Hao, N. B. et al. Macrophages in tumor microenvironment and the progression of tumours. Clin. Dev. Immunol. 2012, 948098 (2012).
41. Wang, Q. et al. Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages. Cell Res. 20, 701-712 (2010).
42. Ferrante, C. J. et al. The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Rh) signaling. Inflammation 36, 921-931 (2013).
43. Lefrancais, E. et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc. Natl Acad. Sci. USA 109, 1673-1678 (2012).
44. Wang, S., Liu, Z., Wang, L., Zhang, X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol. Immunol. 6, 327-334 (2009).
45. Hayakawa, H., Hayakawa, M., Kume, A., Tominaga, S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J. Biol. Chem. 282, 26369-26380 (2007).
46. Seidelin, J. B. et al. IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis. J. Gastroenterol. 50, 180-190 (2015).
47. Edin, S., Wi kberg, M. L., Rutegd, J., Oldenborg, P. A., Palmqvist, R. Phenotypic skewing of macrophages in vitro by secreted factors from colorectal cancer cells. PLoS ONE 8, e74982 (2013).
48. Smithgall, M. D. et al. IL-33 amplifies both Th1-and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int. Immunol. 20, 1019-1030 (2008).
49. Kang, J. C., Chen, J. S., Lee, C. H., Chang, J. J., Shieh, Y. S. Intratumoural macrophage counts correlate with tumor progression in colorectal cancer. J. Surg. Oncol. 102, 242-248 (2010).
50. Sakata, K. et al. Establishment and characterization of high-and low-lungmetastatic cell lines derived from murine colon adenocarcinoma 26 tumor line. Jpn. J. Cancer Res. 87, 78-85 (1996).
51. Shimojo, Y. et al. Attenuation of reactive oxygen species by antioxidants suppresses hypoxia-induced epithelial-mesenchymal transition and metastasis of pancreatic cancer cells. Clin. Exp. Metastasis 30, 143-154 (2013).
52. Liu, W., Guan, M., Hu, T., Gu, X., Lu, Y. Re-expression of AKAP12 inhibits progression and metastasis growth of colorectal carcinoma in vivo and in vitro. PLoS ONE 6, e24015 (2011).
53. Yin, H. et al. Pretreatment with soluble ST2 reduces warm hepatic ischemia/reperfusion injury. Biochem. Biophys. Res. Commun. 351, 940-946 (2006).
54. Song, Y. K., Liu, F., Zhang, G., Liu, D. Hydrodynamics-based transfection: simple and efficient method for introducing and expressing transgenes in animals by intravenous injection of DNA. Methods Enzymol. 346, 92-105 (2002).
55. Tentori, L. et al. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur. J. Cancer 43, 2124-2133 (2007).
56. Baker, M. et al. Use of the mouse aortic ring assay to study angiogenesis. Nat. Protoc. 7, 89-104 (2011).
57. Ishikawa, K. et al. ROS-generating mitochondrial DNA mutations can regulate tumour cell metastasis. Science 320, 661-664 (2008).